| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e9bca1120ab9d2f65b138f53e3eda4d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0356
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 |
| filingDate |
2013-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da79033f295d32cd6b40870253c5d2eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec031531839c62ca54d4dec5ac7cc9ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4486e1c82cb30b68417b3a812dc7743 |
| publicationDate |
2013-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20130143532-A |
| titleOfInvention |
Preparation of patient-specific glioblastoma animal model and its use |
| abstract |
(A) dividing the glioblastoma tissue isolated from the patient into four or more compartments and collecting one or more pieces in each compartment; (b) isolating the glioblastoma cells in a single cell unit from the mixture of the collected fragments; And (c) transplanting the grafted sample containing the glioblastoma cells isolated in step (b), in a brain of an immunodeficient mouse, in a stereotaxic manner. A method for screening a therapeutic agent for a glioblastoma using the mouse model, and an information providing method for selecting a method for treating a patient-customized glioblastoma using the mouse model. The glioblastoma mouse model according to the present invention shows the genetic, morphological and pathological characteristics of maternal cancer equally, and is useful because it is possible to select a method of treating or treating a patient-customized glioblastoma therapeutic agent safely and effectively. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018155952-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190121499-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102048963-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019203534-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220114774-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019235732-A1 |
| priorityDate |
2012-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |